ロード中...
Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors
Breast cancer patients who are HER2-positive receive targeted inhibitors to HER2, including trastuzumab and lapatinib. While patients benefit from the use of HER2 inhibitors, many fail therapy and almost all patients become resistant to treatment, indicating a critical need to prevent treatment fail...
保存先:
| 出版年: | Breast Cancer Res Treat |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4342830/ https://ncbi.nlm.nih.gov/pubmed/25515931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3227-9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|